Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 304

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

Clinical Outcomes of Pulmonary Arterial Hypertension in Patients Carrying an ACVRL1 ( ALK1 ) Mutation

Girerd, Barbara, Montani, David, Coulet, Florence, Sztrymf, Benjamin, Yaici, Azzeddine, Jaïs, Xavier, Tregouet, David, Reis, Abilio, Drouin-Garraud, Valérie, Fraisse, Alain, Sitbon, Olivier, O'Callaghan, Dermot S., Simonneau, Gérald, Soubrier, Florent, Humbert, Marc·2010·American Journal of Respiratory and Critical Care Medicine

Abstract

RATIONALE: Activin A receptor type II-like kinase-1 (ACVRL1, also known as ALK1) mutation is a cause of hereditary hemorrhagic telangiectasia (HHT) and/or heritable pulmonary arterial hypertension (PAH). OBJECTIVES: To describe the characteristics of patients with PAH carrying an ACVRL1 mutation. METHODS: We reviewed clinical, functional, and hemodynamic characteristics of 32 patients with PAH carrying an ACVRL1 mutation, corresponding to 9 patients from the French PAH Network and 23 from literature analysis. These cases were compared with 370 patients from the French PAH Network (93 with a bone morphogenetic protein receptor type 2 [BMPR2] mutation and 277 considered as idiopathic cases without identified mutation). Distribution of mutations in the ACVRL1 gene in patients with PAH was compared with the HHT Mutation Database. MEASUREMENTS AND MAIN RESULTS: At diagnosis, ACVRL1 mutation carriers were significantly younger (21.8 +/- 16.7 yr) than BMPR2 mutation carriers and noncarriers (35.7 +/- 14.9 and 47.6 +/- 16.3 yr, respectively; P < 0.0001). In seven of the nine patients from the French PAH Network, PAH diagnosis preceded manifestations of HHT. ACVRL1 mutation carriers had better hemodynamic status at diagnosis, but none responded to acute vasodilator challenge and they had shorter survival when compared with other patients with PAH despite similar use of specific therapies. ACVRL1 mutations in exon 10 were more frequently observed in patients with PAH, as compared with what was observed in the HHT Mutation Database (33.3 vs. 5%; P < 0.0001). CONCLUSIONS: ACVRL1 mutation carriers were characterized by a younger age at PAH diagnosis. Despite less severe initial hemodynamics and similar management, these patients had worse prognosis compared with other patients with PAH, suggesting more rapid disease progression.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1164/rccm.200908-1284oc

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 41 references

Cited by

See all 304

Metadata

Authors
Girerd, B., Montani, D., Coulet, F., Sztrymf, B., Yaici, A., Jaïs, X., Tregouet, D., Reis, A., Drouin-Garraud, V., Fraisse, A., Sitbon, O., O'Callaghan, D. S., Simonneau, G., Soubrier, F., & Humbert, M.
Venue
American Journal of Respiratory and Critical Care Medicine
Published
2010-04-15
Volume
181
Issue
8
Pages
851-861
ISSN
  • 1073-449X (ISSN-L)
  • 1535-4970
OpenAlex
W1971012582
Cited by
304
References
41
FWCI
20.66
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical Outcomes of Pulmonary Arterial Hypertension in Patients Carrying an ACVRL1 ( ALK1 ) Mutation. https://app.cochat.ai/papers/10.1164/rccm.200908-1284oc
The paper
Girerd, B., Montani, D., Coulet, F., Sztrymf, B., Yaici, A., Jaïs, X., Tregouet, D., Reis, A., Drouin-Garraud, V., Fraisse, A., Sitbon, O., O'Callaghan, D. S., Simonneau, G., Soubrier, F., & Humbert, M. (2010). Clinical Outcomes of Pulmonary Arterial Hypertension in Patients Carrying an ACVRL1 ( ALK1 ) Mutation. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/rccm.200908-1284oc

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.